Takeda Pharmaceutical Files 6-K for March 2024
Ticker: TKPHF · Form: 6-K · Filed: Mar 27, 2024 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Mar 27, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Takeda filed a 6-K for March 2024, confirming its reporting status and Tokyo HQ.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on March 27, 2024, to report information for the month of March 2024. The filing indicates Takeda is a foreign private issuer and files annual reports under Form 20-F. The company's principal executive offices are located in Tokyo, Japan.
Why It Matters
This filing serves as an update for investors regarding Takeda's ongoing reporting requirements as a foreign private issuer with the SEC.
Risk Assessment
Risk Level: low — This is a routine filing confirming reporting status and company information, with no new material financial or operational disclosures.
Key Players & Entities
- TAKEDA PHARMACEUTICAL COMPANY LIMITED (company) — Filer
- 0001395064-24-000020 (filing_id) — Accession Number
- 20240327 (date) — Filing Date
- 001-38757 (company_id) — SEC File Number
- Tokyo (location) — Principal Executive Offices
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer.
Who is the filer of this report?
The filer is TAKEDA PHARMACEUTICAL COMPANY LIMITED.
What period does this report cover?
This report is for the month of March 2024.
Where are Takeda's principal executive offices located?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan.
Under which form does Takeda file its annual reports?
Takeda files its annual reports under Form 20-F.
Filing Stats: 1,027 words · 4 min read · ~3 pages · Grade level 15.2 · Accepted 2024-03-27 06:34:20
Filing Documents
- form6k_032724.htm (6-K) — 43KB
- 0001395064-24-000020.txt ( ) — 44KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date March 27, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller News Release Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting OSAKA, Japan, March 27, 2024, and CAMBRIDGE, Massachusetts, March 26, 2024 - Takeda (TSE4502NYSETAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors at the 148th Ordinary General Meeting of Shareholders to be held on June 26, 2024. Mr. Milano Furuta, currently president of the Japan Pharma Business Unit (JPBU), will succeed Mr. Constantine Saroukos as chief financial officer (CFO) effective April 1, 2024. Takeda will propose Mr. Furuta as a new candidate for board director at the Ordinary General Meeting of Shareholders. If approved by shareholders, Mr. Furuta will join the Board effective June 26, 2024. Mr. Constantine Saroukos, who expressed his intention to retire as CFO, will leave the Board on June 26, 2024 upon the expiration of his term. Candidates for Directors Who Are Not Audit and Supervisory Committee Members Name Category Expected Role Christophe Weber Internal Existing Representative Director, President Chief Executive Officer Andrew Plump Internal Existing Director, President, Research Development Milano Furuta Internal New Director, Chief Financial Officer Masami Iijima External Existing External Director, Chair of the Board Meeting Olivier Bohuon External Existing External Director Ian Clark External Existing External Director Steven Gillis External Existing External Director John Maraganore External Existing External Director Michel Orsinger External Existing External Director Miki Tsusaka External Existing External Dire